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Summary Fifty-two previously untreated patients with advanced non-small-cell lung cancer (NSCLC) were
treated on a 14 day cycle with cisplatin (60 mg m2 iv.) and vindesine (3 mg m-2 i.v.) on day 1, followed by a
3 day continuous infusion of 5-fluorouracil (800 mg m-2 day-') starting on day 8. An overall response rate of
40.4% was observed in 47 evaluable patients, which included one complete response and 18 partial responses.
Responses were achieved in 61.1% of stage 3 patients and 27.6% of stage 4 patients. The median progression-
free interval was 19.3 weeks, and median survival time was 41.6 weeks (47.1 weeks for patients with stage 3
disease and 38.7 weeks for those with stage 4 disease). Toxicity was well tolerated. Gastrointestinal and renal
toxicities did not exceed WHO grade 2. Grade 3 or 4 leucopenia and anaemia occurred in nine (19%) and four
(9%) patients respectively, but only grade 2 thrombocytopenia was observed. Phlebitis at the infusion site was
observed in 24 patients (53%). This treatment programme achieved a response rate similar to other active
combination regimens for the treatment of advanced NSCLC, and was less toxic.
Keywords: non-small-cell lung cancer; combination chemotherapy; cisplatin; vindesine; continuous infusion; 5-
fluorouracil
The use of drug combinations in the treatment of advanced
non-small-cell lung cancer (NSCLC) has been intensively
investigated. Their use, however, remains controversial.
Cisplatin (CDDP) in combination with vinca alkaloids,
vindesine (VDS) or vinblastine (VBL), has been widely used
for induction treatment of NSCLC since Gralla et al. (1981)
first demonstrated a response rate of 43%. Response rates of
approximately 30% have since been shown in advanced
NSCLC using a combination of VDS + CDDP (VP) (Elliott
et al., 1984; Dhingra et al., 1985; Kawahara et al., 1991).
Treatment regimens in which one further active chemother-
apeutic agent has been added to vinca alkaloid and cisplatin
have been tried in an attempt to improve response and
survival rates. The combination of mitomycin with VP
(MVP) has been reported to achieve response rates of 20-
61% (Kris et al., 1986; Einhorn et al., 1986; Miller et al.,
1986; Joss et al., 1990; Fukuoka et al., 1991). Although these
intensive combination chemotherapy regimens achieve an
improvement in objective response, serious drug-related
toxicity is often experienced. Active chemotherapeutic regi-
mens that are less toxic would therefore be desirable.
Although 5-fluorouracil (5-FU) shows limited activity as a
single agent in NSCLC, it reacts synergistically with CDDP
against murine tumours (Schabel et al., 1979; Mabel and
Little, 1979). This has prompted clinical studies of the
combination of CDDP and 5-FU against NSCLC. Weiden et
al. (1985) have reported a response rate of 37% in NSCLC
using this combination. Continuous infusion (CI) of 5-FU
has been found to increase the therapeutic response and
decrease myelosuppression compared with the use of bolus
injections (Seifert et al., 1975; Kish et al., 1985). Decker et al.
(1983) found the combination of CDDP and a 5 day infusion
of 5-FU useful in the treatment of head and neck cancers.
They reported a 94% response rate, including a complete
response rate of 63%. In a pilot study by the Mid-Atlantic
Oncology Program, CDDP (120 mg m-2) infused over 24 h
+ CI 5-FU gave a response rate of 47% in advanced
NSCLC (Heim et al., 1986). Toxicology profiles of these
CDDP + 5-FU regimens indicate less haematological and
nephrological toxicity than standard dose VP and MVP
regimens. However, a higher incidence of severe mucositis
was observed, and, if doxorubicin was also included,
clinically significant myelosuppression, similar to that
encountered with VP and MVP regimens, was also
experienced (Ruckdeschel et al., 1981). Although improved
response rates have been achieved, an optimum dose and
schedule has yet to be identified.
These reports encouraged us to perform a phase II trial of
CDDP and VDS in combination with CI 5-FU against
advanced NSCLC. We decided to administer VP separately
from CI 5-FU, in an attempt to minimise toxicity without
affecting efficacy. In most of the earlier studies CDDP and 5-
FU were administered on the same day. The trial was
designed so that CDDP + VDS and CI 5-FU were injected
on alternate weeks. The immediate objectives were to
determine the major objective response rate to this treatment
programme, and to define the toxicities involved. The activity




Our criteria for eligibility were; cytologically or histologically
confirmed NSCLC; measurable disease; and Eastern Co-
operative Oncology Group (ECOG) performance status (PS)
score of less than 3; age less than 75 years; no evidence of
CNS metastases; adequate renal (serum creatinine < 1.5 mg
dl-', BUN < 25 mg dl-'), hepatic (serum bilirubin < 1.5 mg
dl-', sGOT and sGPT values less than twice the norm for the
institution) and bone marrow function (WBC > 4000 mm
platelets > 100 000 mm-3; no prior chemotherapy; absence
of other concurrent active malignancies; absence of superior
vena cava syndrome; accessibility for follow-up; and
informed consent to participate in this study.
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Pretreatment andfollow-up studies
Pretreatment evaluation involved taking the patient history,
physical examination, complete blood cell counts (CBCs), a
blood chemistry profile, an electrocardiogram (ECG),
complete urinalysis, bone marrow examination, bone
scintigraphy and chest radiograph and computerised tomo-
graphy of the chest and brain, as well as an ultrasonic study
of the abdomen. A clinical assessment and a plain chest
radiograph were performed each week. In addition, CBC and
biochemical tests were performed twice a week.
Patients were staged according to the TNM classification
system (Mountain, 1986). The severity of drug toxicity was
graded according to the WHO toxicity scales (Miller et al.,
1981).
Drug administration
The treatment scheme is summarised in Figure 1.
The chemotherapy was given intravenously as follows:
CDDP (60 mg m-2) in 500 ml of normal saline over 1 h +
VDS (3 mg m-2) by bolus injection on day 1; and 5-FU (800
mg m-2 day-') by continuous 3 day infusion into a
peripheral vein starting on day 8 (PVF). This treatment was
repeated every 14 days for at least three cycles, so that
CDDP and VDS alternated weekly with a 3 day continuous
infusion of 5-FU. A 25% reduction in drug dosage was
required in subsequent cycles for those patients who
experienced WHO grade 4 myelotoxicity, grade 2 nephro-
toxicity, and/or another severe treatment-related toxicity. For
patients who achieved a response, the treatment was
continued for an additional three cycles. All patients
received at least 2.5 1 of hydration on the day of CDDP
administration with forced diuresis. Treatment then contin-
ued until tumour progression was observed, or until no
further response was achieved over three successive cycles.
Concomitant radiation therapy to the brain and bone was
permitted. Granulocyte colony-stimulating factor (G-CSF)
and other cytokines were not used in this study. Antiemetic
therapy, using methylprednisolone and metoclopramide, was
given at the discretion of the investigator.
Response criteria
Patients were evaluated for response after three treatment
cycles. A complete response (CR) was defined as complete
disappearance of all measurable disease for at least 4 weeks
without appearance of any new lesions. A partial response
(PR) was defined as a 50% or more reduction in the sum of
the products of the two longest perpendicular diameters of
measurable lesions for a least 4 weeks; no change (NC) was
defined as a reduction of less than 50% to an increase of less
than 25% in measurable disease, without the appearance of
new lesions. Progressive disease (PD) was defined as an
increase of more than 25% in the size of any measurable
lesion, or the appearance of new lesions.
Survival was calculated from the start of treatment to
death or the date of the last follow-up, using the actuarial
method of Kaplan-Meier. The exact confidence intervals for
the response rates were calculated according to the formula
proposed by Ghosh (1979).
Results
Patient characteristics
Fifty-two patients were entered into this study between
February 1986 and October 1992.
Patient characteristics are summarised in Table I. Of the
52 patients registered, five were ineligible: two had received
prior chemotherapy; two were more than 75 years old; and
one had another concomitant malignant neoplasm. Of the 47
evaluable patients, 83% (39/47) were men. A total of 53% of
cases (25/47) were adenocarcinoma, 34% (16/47) were
squamous cell carcinoma and 13% (6/47) were large-cell
carcinoma. A total of 17% of patients (8/47) had clinical
stage 3A disease, 21% (10/47) has stage 3B disease and 62%
(29/47) had stage 4 disease. A total of 79% (37/47) had a PS
score of 0- 1. The median number of treatment cycles
administered was three (range 1 -6). Two out of the 18
patients with stage 3 disease received a full dose of thoracic
irradiation (5000 cGy) after completing the chemotherapy.
Response
The objective responses are shown in Table II. Of the 47
evaluable patients, one patient achieved CR (2%) and 18
patients achieved PR (38.3%), giving an overall response rate
of 40.4% (95% confidence interval, 26.3-54.5%). NC was
documented in 23 cases (48.9%), and PD in three cases
(6.4%). Two other patients died of other diseases (one patient
died of cerebral haemorrhage and the other died of diabetic
complications). Objective responses were observed in 9/16
cases of squamous cell carcinoma (56.3%) and in 10/31 cases
of non-squamous cell carcinoma (32.3%). The response rates
for patients with stage 3 and stage 4 disease were 61.1% and
27.6% respectively. For stage 4 disease, 42.9% of squamous
cell carcinoma patients achieved remissions, almost twice the
figure for non-squamous cell carcinoma patients (22.7%). For
patients with stage 3 disease, the response rates were 66.7%
and 55.5% respectively. The median progression-free interval
was 19.3 weeks.
Thirty-three out of 47 patients had died by the time of
analysis. The overall median survival for the 47 patients was
41.6 weeks. The median survival for patients with stage 3
Time (weeks)
1 12 1 3 4 5 6
CDDP 60 mg m 2 days 1,15,29 i
VDS 3 mg m-2 days 1,15,29 +
5-FU 800 mg m 2 days 8-10
22-24
36-38





Figure 1 Schema of the treatment protocol.






Median (range) 65 (48-74)
Histology
Adenocarcinoma 25
Squamous cell carcinoma 16
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Table II Tumour response and survival of 47 evaluable patients
Stagel Number of Response Response Survival
histology patients CR PR rate (G) I year (%) 2 year (o)
Stage
III 18 1 10 61.1 65.4 35.0
IV 29 8 27.6 40.0 10.8
Histology
Squamous cell carcinoma
III 9 1 5 66.7 62.2 20.7
IV 7 3 42.9 57.1 19.1
III +IV 16 1 8 56.3 60.0 14.3
Adenocarcinoma
III 8 5 62.5 83.3 62.5
IV 17 5 29.4 28.6 14.3
III +IV 25 10 40.0 43.8 26.3
Large cell carcinoma
III 1 0 0 0
IV 5 0 50.0 0
III +IV 6 0 40.0 0
Non-Sq
III 9 5 55.5 71.4 53.6
IV 22 5 22.7 33.4 7.4
III +IV 31 10 32.3 43.5 17.9




CR, complete response; PR, partial response; Non-sq, adenocarcinoma +large cell carcinoma.
Table III Toxicity (n=47)
WHO grade
Toxicity 1 2 3 4
Leucopenia 9 (19) 18 (38) 8 (17) 1 (2)
Thrombocytopenia 7 (15) 2 (4) 0 0
Anaemia (Hb) 26 (55) 9 (19) 4 (9) 0
Nephrotoxicity (creatinine) 2 (4) 0 0 0
Hepatotoxicity (sGOT/GPT) 9 (19) 1 (2) 0 0
Vomiting/nausea 14 (30) 7 (15) 0 0
Diarrhoea 7 (15) 0 0 0
Alopecia 16 (34) 12 (26) 2 (4) 0
Peripheral neuropathy 8 (17) 1 (2) 0 0
Fever 11 (23) 4 (9) 0 0
Phlebitisa 13 (28) 11 (23)
Values represent number ofpatients (%). aPhlebitis: grade 1, mild; grade 2, moderate.
disease was 47.1 weeks, compared with 38.7 weeks for those
with stage 4 disease. No significant difference in survival was
observed between the patients with squamous cell carcinoma
(median survival 50.6 weeks) and those with non-squamous
cell carcinoma (median survival 38.9 weeks). There were too
few patients to allow us to attach statistical significance to the
difference in survival by histology. However, the 1 year and 2
year survival rates for patients with stage 3 squamous cell
carcinoma were 62.2% and 20.7% respectively, and 71.4%
and 53.6% respectively for patients with stage 3 non-
squamous cell carcinoma. For patients with stage 4 disease,
the 1 year and 2 year survival rates were respectively 57.1%
and 19.1% for squamous cell carcinoma, and 33.4% and
7.4% for non-squamous cell carcinoma.
Toxicity
The toxicities encountered are summarised in Table III. The
most frequent major toxic effect was myelosuppression, but
this was of a mild degree. Grade 3 or 4 leucopenia was
observed in nine patients (19%), but only grade 2
thrombocytopenia was observed and only in two patients
(4%). Grade 1 or 2 anaemia occurred in 35 patients (74%)
and grade 3 or 4 in four patients (9%). Non-haematological
toxicity was generally mild: 21 patients (45%) suffered
vomiting, but this never exceeded grade 2; grade 1 diarrhoea
was observed in seven patients (15%); and peripheral
neuropathy in nine patients (19%). A transient rise in serum
creatinine levels (>2.0 mg ml-') occurred in two patients
(4%), and elevation of sGOT and/or sGPT (> 100 U L-l) in
one patient (2%), none of whom required specific therapy.
No stomatitis was observed. Phlebitis at the site of drug
administration was noted in 24 patients (51%); all of these
improved under conservative management. Pigmentation of
the overlying skin was seen in 18 (38%) patients. Grade 1
alopecia was seen in 16 patients (34%) and grade 2 in 12
patients (26%).
Discussion
The observed response rate of 40.4% with a median survival
of 41.6 weeks for patients with advanced NSCLC receiving
PVF therapy is similar to that recently reported with several-aMesk-e and cosWbuusl hEused 5-FU i NSCLC
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investigators (Fukuoka et al., 1991, 1992) for the MVP
regimen using CDDP in moderate doses (80 mg m-3).
Patients with clinical stage 3 and stage 4 disease were
included in this trial. Objective responses were achieved in 11,
18 (61.1%) stage 3 patients and in 8/29 (27.6%) stage 4
patients. In the report on the MVP regimen using a moderate
CDDP dose, the response rates for stage 3 and stage 4
NSCLC were 44% and 56% respectively (Fukuoka et al.,
1992).
The combination of CDDP + 5-FU has been most
effective against squamous cell lung cancer (Weiden et al.,
1985), and squamous cell head and neck cancer (Decker et
al., 1983). Klastersky et al. (1990) have demonstrated that
squamous cell carcinoma is associated with a significantly
higher response rate than adenocarcinoma in a randomised
study comparing CDDP or carboplatin with etoposide in
patients with NSCLC. We achieved a better response rate im
squamous cell carcinoma (56.3%) than in non-squamous cell
carcinoma (32.3%), using our PVF therapy.
Fukuoka et al. (1992) reviewed the results ofMVP therapy
for advanced NSCLC, and showed that MVP regimens using
moderate- or high-dose CDDP (75-120 mg m-2) achieved a
response rate of49%, whereas the rate was 30% for low-dose
CDDP (60 mg m-' or less). They concluded that CDDP
should be given at a dose of 75 mg m-2 or more. To
maximise chemotherapeutic activity against NSCLC, many
investigators are seeking maximal dose intensity for the drug
combinations. However, this strategy is often associated with
severe toxicity. Weekly administration and an intravenous CI
schedule for several agents may improve efficacy and decrease
toxicity, compared with the use of conventional i.v. bolus
injections (Jacobs et al., 1978; Carlson and Sikic, 1983;
Vogelzang, 1984; Saito et al., 1990; Miles et al., 1991). For
some drugs, conventional intermittent scheduling every 3-4
weeks may be inferior to alternative means of drug delivery
(O'Dwyer and Comis, 1989). In a randomised trial comparing
CDDP + CI 5-FU with CDDP + bolus injections of 5-FU,
the latter treatment schedule was clearly inferior in terms of
the response achieved (Kish et al., 1985). The major
advantage of using a CI delivery of 5-FU instead of bolus
injection is a marked reduction in bone marrow toxicity
(Sikic, 1986). In 1991, the Cancer and Leukaemia Group B
reported the result of a random study comparing CDDP +
CI 5-FU with CDDP + CI 5-FU + VBL for NSCLC, which
showed that neither regimen was effective, and that toxicities
were more frequent and more severe in the latter (Richards et
al., 1991). However, their treatment was administered using a
standard intermittent schedule every 4 weeks.
To minimise toxicity, we separated the administration of
CDDP + VDS and CI 5-FU in the treatment schedule, so
that CDDP + VDS and a 3 day CI 5-FU were given on
alternate weeks. Although this PVF schedule employed a low
dose of CDDP (60 mg m-2), the response rate was better
than that to CDDP (100 mg m-2) + CI 5-FU (Weiden et al.,
1985), or to a 24 h infusion of CDDP (100 mg m-2) + CI 5-
FU + etoposide (Rosenthal et al., 1992). Furthermore, our
results were similar to those observed using a weekly schedule
of CDDP and CI 5-FU + VBL, and to those using CI
CDDP + 5-FU + bolus methotrexate (Lynch et al., 1992).
The toxicity profile for the weekly CDDP-based regimen
used in the Southwest Oncology Group Study was similar to
the standard-dose regimen (Higano et al., 1991). The most
active VP and MVP regimens for advanced NSCLC also
cause moderate or severe myelosuppression (Luedke et al.,
1990; Fukuoka et al., 1992). However, the incidence of severe
haematotoxicity was low and well tolerated using our PVF
regimen. Vomiting was experienced by most patients, but
never exceeded grade 2 and could easily be controlled with
antiemetics. The development of chemical phlebitis at the
infusion site occurred in 51% of the patients, which
sometimes necessitated the replacement of the peripheral
venous catheter. Phlebitis has been reported in 45% of
patients treated with CDDP + CI 5-FU (Verweij et al..
1989). A high n'sk of cardiovascular toxicity has also been
reported for 5-FU (Pottage et al., 1978; Labianca et al..
1982), but we observed no such side-effect.
There were two deaths from other diseases during our
study. One hypertensive patient, whose WBC and thrombo-
cyte count were normal, died of a cerebral haemorrhage. The
other died of a diabetic complication, but without any
indication of the haematological or non-haematological
events associated with the drugs administered. These deaths
cannot therefore be attributed to drug-related toxicity.
In conclusion, this PVF regimen for the treatment of
advanced NSCLC achieved a response rate similar to other
active combination regimens, and was less toxic.
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